Clinical trials and treatment: Effects monitoring

Research output: Contribution to journalArticle

Abstract

Treatment effects monitoring is the act of reviewing accumulated data by treatment group to determine whether a trial should continue unaltered. That monitoring is required for any trial where there is a risk of an aggregate form of harm for subjects because of continued use of an inferior treatment or because of failure to use a superior treatment. Institutional review boards (IRBs), in deciding whether to approve such research, require that (when appropriate) there is adequate provision for monitoring the data collected to ensure the safety of subjects. The focus here is on the conditions necessary to satisfy this requirement. The conditions discussed are timeliness of the monitoring, completeness of data for monitoring, competency of monitors, and freedom of monitors to act and recommend as they deem necessary, regardless of the wishes, desires, or dictates of sponsors. Copyright (C) 1998 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)515-522
Number of pages8
JournalControlled Clinical Trials
Volume19
Issue number6
DOIs
StatePublished - Dec 1998

Fingerprint

Research Ethics Committees
Clinical Trials
Safety
Research

Keywords

  • Clinical trial
  • Monitoring

ASJC Scopus subject areas

  • Pharmacology

Cite this

Clinical trials and treatment : Effects monitoring. / Meinert, Curtis L.

In: Controlled Clinical Trials, Vol. 19, No. 6, 12.1998, p. 515-522.

Research output: Contribution to journalArticle

@article{9a7521b5422746379b673633889055f8,
title = "Clinical trials and treatment: Effects monitoring",
abstract = "Treatment effects monitoring is the act of reviewing accumulated data by treatment group to determine whether a trial should continue unaltered. That monitoring is required for any trial where there is a risk of an aggregate form of harm for subjects because of continued use of an inferior treatment or because of failure to use a superior treatment. Institutional review boards (IRBs), in deciding whether to approve such research, require that (when appropriate) there is adequate provision for monitoring the data collected to ensure the safety of subjects. The focus here is on the conditions necessary to satisfy this requirement. The conditions discussed are timeliness of the monitoring, completeness of data for monitoring, competency of monitors, and freedom of monitors to act and recommend as they deem necessary, regardless of the wishes, desires, or dictates of sponsors. Copyright (C) 1998 Elsevier Science Inc.",
keywords = "Clinical trial, Monitoring",
author = "Meinert, {Curtis L}",
year = "1998",
month = "12",
doi = "10.1016/S0197-2456(98)00027-0",
language = "English (US)",
volume = "19",
pages = "515--522",
journal = "Controlled Clinical Trials",
issn = "0197-2456",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Clinical trials and treatment

T2 - Effects monitoring

AU - Meinert, Curtis L

PY - 1998/12

Y1 - 1998/12

N2 - Treatment effects monitoring is the act of reviewing accumulated data by treatment group to determine whether a trial should continue unaltered. That monitoring is required for any trial where there is a risk of an aggregate form of harm for subjects because of continued use of an inferior treatment or because of failure to use a superior treatment. Institutional review boards (IRBs), in deciding whether to approve such research, require that (when appropriate) there is adequate provision for monitoring the data collected to ensure the safety of subjects. The focus here is on the conditions necessary to satisfy this requirement. The conditions discussed are timeliness of the monitoring, completeness of data for monitoring, competency of monitors, and freedom of monitors to act and recommend as they deem necessary, regardless of the wishes, desires, or dictates of sponsors. Copyright (C) 1998 Elsevier Science Inc.

AB - Treatment effects monitoring is the act of reviewing accumulated data by treatment group to determine whether a trial should continue unaltered. That monitoring is required for any trial where there is a risk of an aggregate form of harm for subjects because of continued use of an inferior treatment or because of failure to use a superior treatment. Institutional review boards (IRBs), in deciding whether to approve such research, require that (when appropriate) there is adequate provision for monitoring the data collected to ensure the safety of subjects. The focus here is on the conditions necessary to satisfy this requirement. The conditions discussed are timeliness of the monitoring, completeness of data for monitoring, competency of monitors, and freedom of monitors to act and recommend as they deem necessary, regardless of the wishes, desires, or dictates of sponsors. Copyright (C) 1998 Elsevier Science Inc.

KW - Clinical trial

KW - Monitoring

UR - http://www.scopus.com/inward/record.url?scp=0032430615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032430615&partnerID=8YFLogxK

U2 - 10.1016/S0197-2456(98)00027-0

DO - 10.1016/S0197-2456(98)00027-0

M3 - Article

C2 - 9875833

AN - SCOPUS:0032430615

VL - 19

SP - 515

EP - 522

JO - Controlled Clinical Trials

JF - Controlled Clinical Trials

SN - 0197-2456

IS - 6

ER -